Skip to main content
Log in

Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline

  • Special Articles
  • Published:
Journal of Clinical Sleep Medicine Aims and scope Submit manuscript

Abstract

Introduction:

This guideline establishes clinical practice recommendations for the management of rapid eye movement sleep behavior disorder (RBD) in adults.

Methods:

The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths based on a systematic review of the literature and an assessment of the evidence using Grading of Recommendations, Assessment, Development and Evaluation methodology. The task force provided a summary of the relevant literature and the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations.

Good Practice Statement:

The following good practice statement is based on expert consensus, and its implementation is necessary for the appropriate and effective management of patients with RBD: It is critically important to help patients maintain a safe sleeping environment to prevent potentially injurious nocturnal behaviors. In particular, the removal of bedside weapons, or objects that could inflict injury if thrown or wielded against a bed partner, is of paramount importance. Sharp furniture like nightstands should be moved away or their edges and headboard should be padded. To reduce the risk of injurious falls, a soft carpet, rug, or mat should be placed next to the bed. Patients with severe, uncontrolled RBD should be recommended to sleep separately from their partners, or at the minimum, to place a pillow between themselves and their partners.

Recommendations:

The following recommendations, with medications listed in alphabetical order, are a guide for clinicians in choosing a specific treatment for RBD in adults. Each recommendation statement is assigned a strength (“strong” or “conditional”). A “strong” recommendation (ie, “We recommend…”) is one that clinicians should follow under most circumstances. A “conditional” recommendation (ie, “We suggest…”) is one that requires that the clinician use clinical knowledge and experience and strongly consider the patient’s values and preferences to determine the best course of action.

Adult patients with isolated RBD

  1. 1.

    The AASM suggests that clinicians use clonazepam (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)

  2. 2.

    * The AASM suggests that clinicians use immediate-release melatonin (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)

  3. 3.

    * The AASM suggests that clinicians use pramipexole (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)

  4. 4.

    The AASM suggests that clinicians use transdermal rivastigmine (vs no treatment) for the treatment of isolated RBD in adults with mild cognitive impairment. (CONDITIONAL)

Adult patients with secondary RBD due to medical condition

  1. 5.

    * The AASM suggests that clinicians use clonazepam (vs no treatment) for the treatment of secondary RBD due to medical condition in adults. (CONDITIONAL)

  2. 6.

    * The AASM suggests that clinicians use immediate-release melatonin (vs no treatment) for the treatment of secondary RBD due to medical condition in adults. (CONDITIONAL)

  3. 7.

    The AASM suggests that clinicians use transdermal rivastigmine (vs no treatment) for the treatment of secondary RBD due to medical condition (Parkinson disease) in adults. (CONDITIONAL)

  4. 8.

    * The AASM suggests that clinicians not use deep brain stimulation (DBS; vs no treatment) for the treatment of secondary RBD due to medical condition in adults. (CONDITIONAL)

Adult patients with drug-induced RBD

  1. 9.

    * The AASM suggests that clinicians use drug discontinuation (vs drug continuation) for the treatment of drug-induced RBD in adults. (CONDITIONAL)

* The Recommendations section of this paper includes remarks that provide additional context to guide clinicians with implementation of this recommendation.

Citation:

Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: An American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2023;19(4):759–768.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

AASM:

American Academy of Sleep Medicine

DBS:

deep brain stimulation

DLB:

dementia with Lewy bodies

MCI:

mild cognitive impairment

PD:

Parkinson disease

PSG:

polysomnography

RBD:

rapid eye movement sleep behavior disorder

REM:

rapid eye movement

RLS:

restless legs syndrome

TF:

task force

5-HT RBD:

5-hydroxytryptamine (serotonergic) RBD

REFERENCES

  1. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.

    Google Scholar 

  2. Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2023;19(4):769–810.

    Google Scholar 

  3. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.

    Google Scholar 

  4. Morgenthaler TI, Deriy L, Heald JL, Thomas SM. The evolution of the AASM clinical practice guidelines: another step forward. J Clin Sleep Med. 2016;12(1):129–135.

    Google Scholar 

  5. Howell MJ. Rapid eye movement sleep behavior disorder and other rapid eye movement parasomnias. Continuum (Minneap Minn). 2020;26(4):929–945.

    Google Scholar 

  6. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med. 2013;9(5):475–480.

    Google Scholar 

  7. Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep. 2018;41(2):zsx197.

    Google Scholar 

  8. Teman PT, Tippmann-Peikert M, Silber MH, Slocumb NL, Auger RR. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med. 2009;10(1):60–65.

    Google Scholar 

  9. Ju YE. Rapid eye movement sleep behavior disorder in adults younger than 50 years of age. Sleep Med. 2013;14(8):768–774.

    Google Scholar 

  10. Tabatabai GM, Boeve AR, Commers N, et al. Time course for phenoconversion to a defined neurodegenerative disease in women with idiopathic REM sleep behavior disorder with and without antidepressant use. (S14.007). Neurology. 2017;88(16 Supplement):S14.007.

    Google Scholar 

  11. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.

    Google Scholar 

  12. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694.

    Google Scholar 

  13. Arnaldi D, Latimier A, Leu-Semenescu S, Vidailhet M, Arnulf I. Loss of REM sleep features across nighttime in REM sleep behavior disorder. Sleep Med. 2016;17:134–137.

    Google Scholar 

  14. Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19(2):153–157.

    Google Scholar 

  15. Brunetti V, Losurdo A, Testani E, et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267–273.

    Google Scholar 

  16. Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. Nat Rev Dis Primers. 2018;4(1):19.

    Google Scholar 

  17. Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72(6):707–712.

    Google Scholar 

  18. Huecker MR, Smiley A, Saadabadi A. Bupropion. Treasure Island, FL: StatPearls Publishing; 2021.

    Google Scholar 

  19. Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84(11):1104–1113.

    Google Scholar 

  20. Chiong W, Tsou AY, Simmons Z, Bonnie RJ, Russell JA; on behalf of the Ethics, Law, and Humanities Committee (a joint committee of the American Academy of Neurology, American Neurological Association, and Child Neurology Society). Ethical considerations in dementia diagnosis and care. Neurology. 2021;97(2):80–89.

    Google Scholar 

  21. McCarter SJ, Boeve BF, Graff-Radford NR, Silber MH, St. Louis EK. Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise? Sleep. 2019;42(6):zsz064.

    Google Scholar 

Download references

ACKNOWLEDGMENTS

The task force thanks and acknowledges the early contributions of Jonathan Heald, MA, a former AASM employee. The task force thanks and acknowledges the contributions of Michael Belleville and Raymond Merrell, who served as patient representatives for this guideline. The task force also thanks Isabelle Arnulf, MD, PhD (Pitié-Salpêtrière Hospital, Paris, France); Madeleine Grigg-Damberger, MD (University of New Mexico School of Medicine, Albuquerque, NM); and Joyce Lee-Iannotti, MD (Banner - University Medical Center, Phoenix, AZ) for serving as external reviewers of this document and providing valuable feedback. The guideline was endorsed by the International RBD Study Group, Project Sleep, and Wake Up Narcolepsy and affirmed by the American Academy of Neurology and the American Geriatrics Society.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Howell MD.

Additional information

Address correspondence to: Michael Howell, MD, Department of Neurology, University of Minnesota, 516 Delaware Street SE, Minneapolis, MN 55455; Email: howel020@umn.edu

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Howell, M., Avidan, A., Foldvary-Schaefer, N. et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 19, 759–768 (2023). https://doi.org/10.5664/jcsm.10424

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.5664/jcsm.10424

Keywords

Profiles

  1. Michael Howell